Showing 2 posts of 2 posts found.

Allogene Therapeutics shares updated ALLO-501/501A phase 1 data in large B-cell lymphoma at ASCO annual meeting

June 5, 2023
Research and Development Allogene, LBCL, Oncology, lymphoma, oncology

Allogene Therapeutics has shared updated data from the phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large …


Ex-Kite execs form a CAR T rival

April 4, 2018
Research and Development, Sales and Marketing Allogene, Pfizer, biotech, drugs, pharma, pharmaceutical

After working to bring through Kite Pharma from the pre-clinical development stage to its final $12 billion acquisition by Gilead, …

Latest content